Design and Development An Overview

The twentyfirst century may obviously record and witness an apparent positive tilt in population demographics ultimately leading to a much healthier, stronger and happier elderly population. 

However, in the 21st century, the ethical pharmaceutical industry has been fully geared towards the production of relatively safer, less toxic, more effective, higher therapeutic index, novel, innovative medicaments that will evidently help the mankind to afford a disease-free society besides, the elder ones with a glaring hope to live a still longer life span. 

Following is the brief description in a chromological order for the development of ethical pharmaceutical industry in the world  

1880s Germany and UK —Hoechst (Germany) and Wellcome (UK) for immunological dmgs. 

1929 USA —Aureomycin (Lederle) Chloromycetin (Parke-Davis) Teramycin (Pfizer)  

---

K.L. Kirk, Selective fluorination in drug design and development, an overview of biochemical rationales, Curr. Top. Med. Chem. 6 (2006) 1447-1456. 

---